Cancer drug Taxotere linked to permanent hair loss

Beasley Allen lawyer Beau Darley joins Beasley Allen Report host and Beasley Allen lawyer Gibson Vance to discuss how an expected, temporary side effect of chemotherapy could prove permanent for patients taking Taxotere, a cancer treatment drug available since 1996. Beau explains Taxotere’s manufacturer, Sanofi-Aventis, failed to inform the FDA, health care providers and the public of the permanent hair loss risk until the FDA forced the company to include a warning on the drug in 2015. The two also discuss how defective medical devices and drugs make it onto the consumer market.


We're here to help!

We live by our creed of “helping those who need it most” and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked * may be required for submission.


Impressed with the Beasley Allen staff

I am very impressed with the Beasley Allen staff. They were very courteous and patiently explained the aspects of my claim in a way I could understand. If I ever have any need of an attorney in the future I will turn to Beasley Allen.

—Philip